M&A / Deals Lilly to acquire CrossBridge Bio for up to $300m Pharmaceutical Business ReviewThe acquisition includes the lead candidate CBB-120, a dual-payload antibody-drug conjugate (ADC) developed to treat cancer.M&A / DealsRead full story pharminent April 15, 2026 Pharmaceutical Business Review The acquisition includes the lead candidate CBB-120, a dual-payload antibody-drug conjugate (ADC) developed to treat cancer. M&A / DealsRead full story Post navigation Previous: Adcendo secures $75m in Series C funding for ADC developmentNext: Lilly to acquire CrossBridge Bio for up to $300m Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
